Objective  To analyze the research trends and hotspots of tenecteplase and provide a reference for clinical research and rational drug use in China.

Methods  A comprehensive search was conducted on tenecteplase studies in the Web of Science database from its inception to April 2024. CiteSpace 6.1.R6 software was used to analysis authors, countries/regions, research institutions, keywords, and co-cited references.

Results  A total of 673 articles were included in this study. The annual publication volume showed an overall upward trend, rapidly increasing in the past three years. The United States, Canada, and Australia were the top 3 countries in terms of publication volume in this field. Among the top 10 institutions in publication volume, 9 were from above 3 countries. The research hotspots were the efficacy and safety of tenecteplase in patients with acute myocardial infarction and acute ischemic stroke. In recent years, research hotspots have mainly focused on the field of acute ischemic stroke.

Conclusion  The application of tenecteplase in the field of acute ischemic stroke is currently a research hotspot. However, there is still a gap between the research level in China and that in developed countries such as the United States. Future research hotspots may still focus on the application of tenecteplase in patients with different types of acute ischemic stroke, suggesting that scholars should pay close attention to this area.

1.Davydov L, Cheng JW. Tenecteplase: a review[J]. Clin Ther, 2001, 23(7): 982-997. DOI: 10.1016/s0149-2918(01)80086-2.

2.霍晓川, 高峰.急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志, 2023, 18(6): 684-711. [Huo XC, Gao F. Chinese guidelines for endovascular treatment of acute ischemic stroke 2023[J]. Chinese Journal of Stroke, 2023, 18(6): 684-711.] DOI: 10.3969/j.issn.1673-5765. 2023.06.010.

3.Roldán-Valadez E, Salazar-Ruiz SY, Ibarra-Contreras R, et al. Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics[J]. Ir J Med Sci, 2019, 188(3): 939-951. DOI: 10.1007/s11845-018-1936-5.

4.Chen CM. Science mapping: a systematic review of the literature[J]. J Data Inform Sci, 2017, 2(2): 1-40. DOI: 10.1515/jdis-2017-0006.

5.van de Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial[J]. Lancet, 199, 354(9180): 716-722. DOI: 10.1016/s0140-6736(99)07403-6.

6.Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction[J]. Lancet, 2001, 358(9282): 605-613. DOI: 10.1016/S0140-6736(01)05775-0.

7.Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study[J]. Eur Heart J, 2006, 27(13): 1530-1538. DOI: 10.1093/eurheartj/ehl088.

8.Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial[J]. JAMA, 2020, 323(13): 1257-1265. DOI: 10.1001/jama.2020.1511.

9.Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction[J]. N Engl J Med, 2013, 368(15): 1379-1387. DOI: 10.1056/NEJMoa1301092.

10.Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acuteischemic stroke: a Meta-analysis[J]. Stroke, 2009, 40(7): 2438-2441. DOI: 10.1161/STROKEAHA.109.552547.

11.李杰, 陈超美, 主编. CiteSpace科技文本挖掘及可视化[M]. 北京: 首都经济贸易大学出版社, 2022: 147-148.

12.陈会生, 杨清武, 程忻. 急性缺血性卒中替奈普酶静脉溶栓治疗中国专家共识[J]. 中国神经精神疾病杂志, 2022, 48(11): 641-651. [Chen HS, Yang QW, Cheng X. Chinese expert consensus on intravenous thrombolysis with tenecteplase for acute ischemic stroke[J]. Chinese Journal of Nervous and Mental Diseases, 2022, 48(11): 641-651.] DOI: 10.3969/j.issn.1002-0152.2022.11.001.

13.曹苑, 崔丽英. 溶栓药物的发展历程[J]. 协和医学杂志, 2020, 11(2): 121-126. [Cao Y, Cui LY. The development process of thrombolytic drugs[J]. Peking Union Medical College Hospital Journal, 2020, 11(2): 121-126.] DOI: 10.3969/j.issn.1674-9081.20190278.

14.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015, 43(5): 380-393. [Chinese Society of Cardiology, Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and treatment of acute ST-segment elevation myocardial infarction [J]. Chinese Journal of Cardiology, 2015, 43(5): 380-393.] DOI: 10.3760/cma.j.issn.0253-3758.2015.05.003.

15.Guerra DR, Karha J, Gibson CM. Safety and efficacy of tenecteplase in acute myocardial infarction[J]. Expert Opin Pharmacother, 2003, 4(5): 791-798. DOI: 10.1517/14656566.4.5.791.

16.Sinnaeve PR, Armstrong PW, Gershlick AH, et al. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: strategic reperfusion early after myocardial infarction (STREAM) 1-year mortality follow-up[J]. Circulation, 2014, 130(14): 1139-1145. DOI: 10.1161/CIRCULATIONAHA.114.009570.

17.Van de Werf F, Ristić AD, Averkov OV, et al. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial[J]. Circulation, 2023, 148(9): 753-764. DOI: 10.1161/CIRCULATIONAHA.123.064521.

18.Logallo N, Novotny V, Assmus J, et al.Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial[J]. Lancet Neurol, 2017, 16(10): 781-788. DOI: 10.1016/S1474-4422(17)30253-3.

19.Kvistad CE, Nass H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial[J]. Lancet Neurol, 2022, 21(6): 511-519. DOI: 10.1016/S1474-4422(22)00124-7.

20.Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet, 2022, 400(10347): 161-169.DOI: 10.1016/S0140-6736(22)01054-6.

21.Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial[J]. Lancet, 2023, 401(10377): 645-654. DOI: 10.1016/S0140-6736(22)02600-9.

22.Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med, 2012, 366(12): 1099-1107. DOI: 10.1056/NEJMoa1109842.

23.Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384(9958): 1929-1935. DOI: 10.1016/S0140-6736(14)60584-5.

24.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. [Chinese Society of Neurology, Cerebrovascular Disease Group of Chinese Society of Neurology. Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9): 666-682.] DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

25.Cheng X, Hong L, Churilov L, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial[J]. Stroke Vasc Neurol, 2024, 9(5): 551-559. DOI: 10.1136/svn-2023-002820.

26.Ospel JM, Singh N, Almekhlafi MA, et al. Early recanalization with alteplase in stroke because of large vessel occlusion in the ESCAPE trial[J]. Stroke, 2021, 52(1): 304-307. DOI: 10.1161/STROKEAHA.120.031591.

27.Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med, 2015, 372(24): 2285-2295. DOI: 10.1056/NEJMoa1415061.

28.Checkouri T, Gerschenfeld G, Seners P, et al. Early recanalization among patients undergoing bridging therapy with tenecteplase or alteplase[J]. Stroke, 2023, 54(10): 2491-2499. DOI: 10.1161/STROKEAHA.123.042691.

29.Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2019, 50(12): e344-e418. DOI: 10.1161/STR.0000000000000211.

30.Berge E, Whiteley W, Audebert H,et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J, 2021, 6(1): I-LXII. DOI: 10.1177/2396987321989865.

31.王聪, 李龙宣. 基于CiteSpace的近10年急性缺血性卒中机械取栓领域文献计量可视化分析[J]. 介入放射学杂志, 2023, 32(5): 478-485. [Wang C,Li LX.A bibliometric and visual analysis of literature in the field of mechanical thrombectomy for acute ischemic stroke in the past decade based on CiteSpace[J]. Journal of Interventional Radiology, 2023, 32(5): 478-485.] DOI: 10.3969/j.issn.1008-794X.2023.05.014.